等待开盘 08-17 09:30:00 美东时间
-0.225
-7.15%
CDT Equity Inc. announces a 1-for-10 reverse stock split to maintain compliance with Nasdaq's bid-price rule. Effective July 17, 2026, every 10 shares will combine into 1 share, with trading resuming on July 20 under the same ticker "CDT." The company's common stock will have a new CUSIP number, and outstanding shares will reduce to approximately 631,077. Fractional shares will be settled with cash. The reverse split aims to ensure continued list...
07-16 12:00
Conduit Pharmaceuticals (NASDAQ:CDT) reported quarterly losses of $(5.56) per share. This is a 99.85 percent increase over losses of $(3.67 thousand) per share from the same period last year.
07-16 06:15
CDT Equity Inc. announced that Sarborg Limited has expanded its Signature Intelligence platform into quantum-assisted coformer selection through SarborgQ, the Company's quantum computing division. Sarborg is integrating its proprietary datasets, AI architecture, and quantum computing to accelerate solid-form development, improve decision-making, and identify new co-crystal, salt, and solid-form opportunities. The initiative aims to enhance Sarbor...
06-26 12:30
Gainers PRF Technologies (NASDAQ:PRFX) stock rose 231.0% to $4.54 during Frida...
05-30 01:06
CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that the Company received a written notice ("Notice") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on
05-29 04:24
CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key
05-27 20:03
CDT Equity Inc. announced the grant of a patent for AZD5904 in male infertility in Canada, completing approval in key markets. The extensive patent coverage and composition of matter application strengthen its IP position for development. AZD5904, originally licensed from AstraZeneca, addresses a significant unmet medical need in a $4.4 billion global market. The Canadian approval enhances global positioning as CDT advances partnering discussions...
05-27 12:00
Gainers BioLine Rx (NASDAQ:BLRX) stock increased by 12.5% to $3.11 during Mond...
05-19 05:05
Sarborg announced that the patent was developed using its proprietary Signature Agent and Multi-Agent platform, supported by its Sarborg 1,600 Disease Database and Sarborg 1,700 Rare Disease Database. According to
05-07 20:38